SK15772002A3 - Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom - Google Patents

Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom Download PDF

Info

Publication number
SK15772002A3
SK15772002A3 SK1577-2002A SK15772002A SK15772002A3 SK 15772002 A3 SK15772002 A3 SK 15772002A3 SK 15772002 A SK15772002 A SK 15772002A SK 15772002 A3 SK15772002 A3 SK 15772002A3
Authority
SK
Slovakia
Prior art keywords
apomorphine
norapomorphine
derivatives
pharmaceutically acceptable
compound
Prior art date
Application number
SK1577-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Pramod K. Gupta
Debra Sutkowski-Markham
Deborah Milkowski
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of SK15772002A3 publication Critical patent/SK15772002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK1577-2002A 2000-04-07 2001-03-29 Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom SK15772002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (1)

Publication Number Publication Date
SK15772002A3 true SK15772002A3 (sk) 2003-09-11

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1577-2002A SK15772002A3 (sk) 2000-04-07 2001-03-29 Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom

Country Status (18)

Country Link
US (1) US6506765B2 (xx)
EP (1) EP1284735A4 (xx)
JP (1) JP2003532640A (xx)
KR (1) KR20030036157A (xx)
CN (1) CN1471395A (xx)
AU (1) AU2001255818A1 (xx)
BG (1) BG107217A (xx)
BR (1) BR0109515A (xx)
CA (1) CA2405419A1 (xx)
CZ (1) CZ20023637A3 (xx)
HU (1) HUP0301773A3 (xx)
IL (1) IL151614A0 (xx)
MX (1) MXPA02009904A (xx)
NO (1) NO20024806D0 (xx)
PL (1) PL361672A1 (xx)
SK (1) SK15772002A3 (xx)
WO (1) WO2001076602A1 (xx)
ZA (1) ZA200207489B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1613323A1 (en) * 2003-04-14 2006-01-11 Vectura Limited Pharmaceutical compositions comprising apomorhine for pulmonary inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
SI2450041T1 (sl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
BR112019014981A2 (pt) 2017-11-24 2020-04-07 H Lundbeck As composto, sal farmaceuticamente aceitável, uso dos mesmos e composição farmacêutica
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ATE290864T1 (de) 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
DK0758895T3 (da) 1994-04-22 2000-06-13 Pentech Pharmaceuticals Inc Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE69709646T2 (de) 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
DK1035833T3 (da) 1997-12-02 2006-01-09 Archimedes Dev Ltd Sammensætning til nasal indgivelse
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
CA2371551A1 (en) * 1999-05-13 2000-11-23 Mario Baraldi Pharmaceutical compositions comprising apocodeine and/or its derivatives

Also Published As

Publication number Publication date
US6506765B2 (en) 2003-01-14
AU2001255818A1 (en) 2001-10-23
MXPA02009904A (es) 2004-09-06
WO2001076602A1 (en) 2001-10-18
US20020002176A1 (en) 2002-01-03
BR0109515A (pt) 2004-08-10
EP1284735A4 (en) 2006-01-11
HUP0301773A2 (hu) 2003-09-29
NO20024806D0 (no) 2002-10-04
JP2003532640A (ja) 2003-11-05
EP1284735A1 (en) 2003-02-26
CZ20023637A3 (cs) 2003-02-12
CN1471395A (zh) 2004-01-28
BG107217A (bg) 2003-05-30
HUP0301773A3 (en) 2006-02-28
PL361672A1 (en) 2004-10-04
CA2405419A1 (en) 2001-10-18
KR20030036157A (ko) 2003-05-09
ZA200207489B (en) 2003-12-18
IL151614A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
SK15772002A3 (sk) Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom
US20090239881A1 (en) Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
US20070099947A1 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
SK11362000A3 (sk) Spôsob zlepšenia sexuálnej dysfunkcie žien
EA005412B1 (ru) Способ лечения сексуальных нарушений
SK15112002A3 (sk) Liečivo na liečenie sexuálnej dysfunkcie pacienta
JPH11501282A (ja) コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体
SK8262001A3 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
SK7422003A3 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2014505113A (ja) 末梢作用性μオピオイドアンタゴニスト
CN111801096B (zh) 癫痫治疗剂
MX2012001290A (es) Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
JP2002518435A (ja) 女性の性機能不全の治療または改善のための方法および組成物
US20020086876A1 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2008523015A (ja) 薬剤４−（ｓ）−（４−アセチル−ピペラジン−１−イル）−２−（ｒ）−（４−フルオロ−２−メチル−フェニル）−ピペラジン−１−カルボン酸，［１−（ｒ）−（３，５−ビス−トリフルオロメチル−フェニル）−エチル］−メチルアミドの使用

Legal Events

Date Code Title Description
FC9A Refused patent application